The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | The combination of ibrutinib and obinutuzumab in CLL
The future of CLL therapy is in combination therapies. Matthew Davids, MD of Dana-Farber Cancer Institute, Boston, MA talks about the combination of novel agent-based oral therapies with CD20 monoclonal antibodies, specifically the combination of ibrutinib and obinutuzumab for relapsed refractory CLL patients. Results from this phase 1b trial have shown a promising approach in terms of efficacy. However, Dr Davids believes that the most useful aspect of this study has been determining the order of administration. The rates of infusional reactions, was lower in the arms of the trial that started ibrutinib first for a month or started both drugs simultaneously. This is a valuable piece of knowledge for the design of future trials involving these two drugs.
